Tue. October 07, 2008
-
Leader-Telegram
October 7, 2008
MELVILLE, NY - OSI Pharmaceuticals and
Genentech, partners in an anti-
cancer drug, said Monday a combination of
Genentech's Avastin and OSI's Tarceva failed ...
MarketWatch
October 7, 2008
were both lower after they reported disappointing results from a Phase III clinical trial that tested Genentech's leading oncology drug Avastin with OSI's ...
TheStreet.com
October 4, 2008
Meanwhile,
Genentech(DNA Quote - Cramer on DNA - Stock Picks) said Thursday after the close that it issued a "Dear
healthcare Provider" letter to tell ...
Baystreet.ca
October 4, 2008
"
Genentech engages in the discovery, development, manufacture and commercialization of pharmaceutical products in
the United States. ...
Genetic Engineering News (press release)
October 4, 2008
Roche,
Genentech, and GlycArt are working together to develop GlycArt's GA101
molecule for various
cancer indications. The agreement covers a license from ...
Trading Markets (press release)
October 4, 2008
Additionally, the alliance includes a licence from GlycArt to
Genentech. The
companies will develop GA101, a humanised anti-CD20 monoclonal antibody ...
Forbes
October 3, 2008
AP 10.03.08, 8:03 AM ET
Genentech Inc. said late Thursday it has informed
physicians that its psoriasis drug Raptiva may have contributed to the development ...
WELT ONLINE
October 2, 2008
In association with this agreement, Genentech, Roche and GlycArt will share certain development costs and Genentech will record $105 million in research and ...
Reuters
October 2, 2008
"The CHF-USD rate has risen by 8 percent since the day Roche announced the offer for Genentech minorities. This essentially prices the deal as 8 percent ...
Reuters
October 2, 2008
Genentech, which is already 55 percent owned by Roche Holding, rejected a $89 per share bid from Roche in mid-August, but speculation about a deal was ...
MarketWatch
September 29, 2008
This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompasses global company ...
BioWorld Online
September 27, 2008
Raymond also said Genentech may stand to gain the most, as far as biotechs go, from the proposed financial system bailout. "If a credible bill is produced ...
Reuters
September 26, 2008
FiercePharma
September 25, 2008
By Tracy Staton Stroke patients should get a clot-busting Genentech drug, even if it's administered a little later than originally advised. ...
News-Times
September 24, 2008
Naperville Sun
September 24, 2008
OSI Pharmaceuticals and
Genentech Inc. have added new warnings to their
cancer drug Tarceva after two patients died of liver damage. 5. ...
Pharmaceutical Business Review
September 24, 2008
Avastin (bevacizumab;
Genentech/Roche) has shown the greatest potential in the ovarian
cancer pipeline to date, with encouraging response rates in heavily ...
Inside Bay Area
September 24, 2008
Larger
companies such as South
San Francisco-based
Genentech have cash and revenue to stay afloat. But smaller firms that have fewer approved products could ...
Boston Globe
September 24, 2008
(Bloomberg) OSI Pharmaceuticals and
Genentech Inc. have added toxicity warnings to the label of their
cancer drug Tarceva after two patients died of liver ...
Pharmalot
September 24, 2008
A Genentech spokeswoman tells Reuters the prescribing info already included a "precaution" about liver damage including fatalities. ...
Washington Observer Reporter
September 21, 2008
... that the tests will soon become widespread. Last year,
Google Inc. invested $3.9 million in 23andMe. Biotech pioneer
Genentech Inc. is another major backer.
First Coast News
September 20, 2008
Yes it's 5:30 and the running journal is on the road this week with Team Genentech.Genentech is the founding sponsor for 26.2 with Donna and their people ...
Motley Fool
September 20, 2008
Don't you wish you could have invested in Genentech when it was small? Or at the very least find the next Genentech before it gets big? ...
InjuryBoard.com
September 19, 2008
The drug Rituxan, marketed by leading US
biotechnology companies Genentech and Biogen Idec, is a unique treatment for arthritis. Rituxan has also been used ...
Pharmaceutical Online (press release)
September 18, 2008
"For large
companies with significant manufacturing capacity such as Amgen or
Genentech, access to biomanufacturing capacity is less critical than for small ...
Schaeffers Research
September 18, 2008
companies seeing a skew towards puts in the previous session:
wells Fargo & Co (WFC),
Genentech (DNA), Nortel Networks (NT),
JP Morgan Chase & Co. ...
TopNews
September 17, 2008
Swiss drugmaker Roche, which is a partner with Genentech in Avastin development, added that the study was not powered to demonstrate an overall survival ...
Reuters
September 17, 2008
VX: Quote, Profile, Research, Stock Buzz) is confident it can secure financing at a reasonable price for the acquisition of Genentech (DNA. ...
San Francisco Chronicle
September 16, 2008
The currency turnaround is chipping at the share price of biotech giant
Genentech Inc. of South
San Francisco, Kantor said. That's because
Genentech's ...
RedOrbit
September 16, 2008
One case involves two different medicines made by the same company, Genentech Inc. One drug, Avastin, is approved, marketed, prescribed and, apparently, ...
NJBIZ
September 15, 2008
Last month, for example, Nutley-based Hoffman-LaRoche Inc. announced it will move its headquarters and facilities to
California, home of
Genentech Inc., ...
Buffalo News
September 15, 2008
One case involves two different medicines made by the same company, Genentech Inc. One drug, Avastin, is approved, marketed, prescribed and, apparently, ...
